Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cancer Biology

Background:

• A novel lead compound, NSC130362, exhibits selective anti-cancer efficacy and safety in normal cells.
• Understanding the molecular target of NSC130362 is crucial for developing safer cancer therapies.

Purpose of the Study:

• To elucidate the target of NSC130362 responsible for its selective anti-cancer activity and safety.
• To conduct structure-activity relationship (SAR) studies on 1,4-naphthoquinines and quinoline-5,8-diones.

Main Methods:

• SAR studies involved cell viability assays using pancreatic cancer (MIA PaCa-2) and breast cancer (HCC1187) cells, alongside normal human hepatocytes.
• Compounds were categorized based on their ability to induce apoptosis selectively in cancer cells or in both cancer and normal cells.
• Inhibition of the mitochondrial electron transfer chain (ETC) was assessed as a key distinguishing activity.

Main Results:

• A library of 1,4-naphthoquinines and quinoline-5,8-diones was synthesized and tested.
• Compounds were identified that selectively induce apoptosis in cancer cells without harming normal cells.
• Inhibition of the mitochondrial ETC was found to be a critical differentiator between non-toxic and toxic compounds.

Conclusions:

• Selective inhibition of the mitochondrial ETC is key to developing anti-cancer compounds with improved potency and safety.
• Quantitative SAR (QSAR) models can be utilized to design effective and non-toxic anti-cancer agents.
• This research provides a foundation for the rational design of next-generation cancer therapeutics.